Pyxis Oncology, Inc. (PYXS)

Pyxis Oncology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	18.86	15.42	19.47	9.66	179.29	274.74
Short-Term Investments	14.14	51.44	107.46	109.63	-	-
Cash & Short-Term Investments	33	66.86	126.93	119.3	179.29	274.74
Cash Growth	-62.90%	-47.33%	6.40%	-33.46%	-34.74%	3300.19%
Other Receivables	-	0.7	-	-	0.6	-
Receivables	-	0.7	-	-	0.6	-
Prepaid Expenses	2.27	0.59	0.76	1.01	1.31	1.76
Restricted Cash	1.47	1.47	1.47	1.47	1.47	1.47
Other Current Assets	-	2.49	3.28	2.82	3.94	0.7
Total Current Assets	36.73	72.11	132.44	124.6	186.61	278.67
Property, Plant & Equipment	18.19	19.42	22.14	24.81	24.77	1.24
Other Intangible Assets	-	-	2.6	24.31	-	-
Other Long-Term Assets	-	-	-	-	-	0.11
Total Assets	54.92	91.52	157.18	173.73	211.38	280.02

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	3.27	10.89	4.86	3.9	7.1	11.95
Accrued Expenses	12.38	8.12	10.73	12.62	23.45	6.33
Current Portion of Leases	1.82	1.69	1.45	1.23	-	0.17
Current Unearned Revenue	-	-	-	7.66	-	-
Other Current Liabilities	10	0.43	0.64	0.36	1.09	0.27
Total Current Liabilities	27.47	21.13	17.68	25.76	31.63	18.71
Long-Term Leases	16.01	16.98	18.75	20.1	18.92	-
Long-Term Deferred Tax Liabilities	-	-	-	2.16	-	-
Total Liabilities	43.48	38.11	36.43	48.02	50.56	18.71

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.06	0.06	0.06	0.05	0.03	0.03
Additional Paid-In Capital	503.18	496.47	484.08	411.82	373.23	353
Retained Earnings	-491.8	-443.18	-363.56	-286.23	-212.44	-91.72
Comprehensive Income & Other	-0	0.05	0.17	0.06	-	-
Total Common Equity	11.44	53.41	120.75	125.7	160.82	261.31
Shareholders' Equity	11.44	53.41	120.75	125.7	160.82	261.31
Total Liabilities & Equity	54.92	91.52	157.18	173.73	211.38	280.02

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	17.83	18.67	20.2	21.33	18.92	0.17
Net Cash (Debt)	15.16	48.18	106.73	97.97	160.37	274.57
Net Cash Growth	-78.18%	-54.85%	8.95%	-38.91%	-41.59%	3661.23%
Net Cash Per Share	0.24	0.78	1.83	2.46	4.85	32.33
Filing Date Shares Outstanding	83.41	62.83	61.59	58.13	36.83	32.22
Total Common Shares Outstanding	63.43	62.69	59.97	44.75	34.96	32.17
Working Capital	9.26	50.97	114.76	98.85	154.98	259.97
Book Value Per Share	0.18	0.85	2.01	2.81	4.60	8.12
Tangible Book Value	11.44	53.41	118.15	101.4	160.82	261.31
Tangible Book Value Per Share	0.18	0.85	1.97	2.27	4.60	8.12
Machinery	-	4.15	4.19	4.52	3.28	1.9
Construction In Progress	-	-	-	-	9.18	-
Leasehold Improvements	-	10.74	10.74	10.96	0.53	0.23

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 26, 2026

Data Sources Report a data error